SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Trillium Therapeutics Inc. TRIL.TO TSX

Toronto Stock Exchan • Healthcare • Biotechnology • CA • CAD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Trillium Therapeutics Inc. (TRIL.TO) is a Biotechnology company in the Healthcare sector, currently trading at $23.33. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $148,000, +19.4%/yr average growth. Net income is $59M (loss), growing at -21%/yr. Net profit margin is -40098.6% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $831,000 against $279M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.94 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $301M.

Analyst outlook: 2 / 5 analysts rate TRIL.TO as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

TRIL.TO SharesGrow Score Overview

45/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TRIL.TO

No analyst coverage available for this stock.

TRIL.TO: +19.4%/yr revenue is, -21%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet TRIL.TO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

TRIL.TO: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 5 analysts rate TRIL.TO as buy (40%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

TRIL.TO: Net profit margin is -40098.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range23.22-23.45

Volume60.42K

Avg Volume (30D)127.47K

Beta (1Y)1.90

Share Statistics

EPS (TTM)-0.70

Shares Outstanding$84.6M

IPO Date2014-04-22

Employees33

CEOJan Skvarka

Financial Highlights & Ratios

Revenue (TTM)$148K

Gross Profit$148K

EBITDA$-58.65M

Net Income$-59.35M

Operating Income$-61.46M

Total Cash$291.17M

Total Debt$831K

Net Debt$-246.77M

Total Assets$300.82M

Price / Earnings (P/E)-33.3

Analyst Forecast

Rating ConsensusHold

Analysts Covering5

Buy 40% Hold 60% Sell 0%

Company Info

CountryCA

ExchangeToronto Stock Exchan

CurrencyCAD

ISINCA89624T1057

Price Chart

TRIL.TO

Trillium Therapeutics Inc. ↗ · Toronto Stock Exchan

Healthcare • Biotechnology

23.22 52WK RANGE 23.45

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message